IBS-trained therapists are hard to find and access. That’s why we’ve developed a validated regulatory cleared digital therapeutic that delivers gut-directed cognitive behavioural therapy for IBS. 63% of patients treated with Mahana IBS in a clinical trial reported a clinically meaningful improvement in IBS symptom severity and saw durable effects for up to a year after their 90 day use.1,2
Sign up to receive your free welcome pack:
The efficacy and safety of Mahana IBS was demonstrated in the ACTIB trial of 558 adult patients with refractory IBS. Mahana helped nearly 2 in 3 people in a clinical trial.1,2
Provide patients with a regulatory-cleared, evidence-based digital therapy, to reduce symptom severity.
Healthcare Professionals in the UK can now access Mahana IBS for patients. Register your interest to receive more information on how we are working with the NHS and healthcare teams and to provide Mahana IBS for their patients.
.png)
Mahana’s cognitive behavioural therapy is gut-directed psychotherapy (GDP) that improves IBS symptom severity by targeting the cognitive factors known to drive symptoms. CBT is the most rigorously tested psychological treatment for IBS.
Mahana enables you to empower all IBS patients with a treatment that has no known side effects.
The gut-brain axis is a bidirectional communication system that links intestinal functions with the emotional and cognitive centers of the brain.
Join leading healthcare professionals who understand the importance of using innovative, validated digital therapeutic treatments to improve patient outcomes.
Explaining to patients the benefits of using Mahana IBS is fast and simple.
We have a variety of patient information leaflets, posters, videos to explain the benefits of Mahana IBS and also comprehensive clinical resources for HCPs.
Mahana IBS gut directed CBT helps patients develop skills in 10 key areas over the course of the 90 day programme to reduce severity of symptoms.
Patients have more information at their fingertips than ever before. That’s why it’s imperative for physicians to anticipate and understand consumer health trends.
Mahana IBS is the first and only FDA cleared digital IBS treatment. With Mahana IBS, physicians can be confident they are prescribing an efficacious and safe digital health treatment
In 2021, the number of people using digital therapeutics is expected to reach 44 million worldwide. Almost double the number of users in 2020.4
We're working with leaders in gastroenterology to ensure patient and healthcare professionals have the tools they need for IBS treatment.
Hazel Everitt, Ph.D, FRCGP
University of Southampton, GP & Professor of Primary Care Research
Emeran Mayer, M.D.
Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience (CNSR)
Jasmine Zia, M.D.
Swedish Medical Center, Gastroenterologist
Rona Moss-Morris, Ph.D
King's College London, Head of Psychology Department, Institute of Psychiatry, Psychology & Neuroscience
